Trials / Completed
CompletedNCT03568656
Study to Evaluate CCS1477 in Advanced Tumours
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 220 (actual)
- Sponsor
- CellCentric Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.
Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Metastatic Breast Cancer
- Non-small Cell Lung Cancer
- Advanced Solid Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CCS1477 | Capsules, oral |
| DRUG | Abiraterone acetate | Abiraterone acetate 500mg tablets plus prednisone/prednisolone |
| DRUG | Enzalutamide | Enzalutamide 40mg capsules/tablets |
| DRUG | Darolutamide | 300mg tablets |
| DRUG | Olaparib | 150mg tablets |
| DRUG | Atezolizumab | 840mg/14ml concentrate for solution for infusion vials |
Timeline
- Start date
- 2018-07-23
- Primary completion
- 2025-07-06
- Completion
- 2025-07-06
- First posted
- 2018-06-26
- Last updated
- 2025-08-08
Locations
19 sites across 6 countries: United States, France, Netherlands, Spain, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03568656. Inclusion in this directory is not an endorsement.